key: cord-0894790-mbwbhdqe
authors: Cory, Theodore J.; Emmons, Russell S.; Yarbro, Johnathan R.; Davis, Kierstin L.; Pence, Brandt D.
title: Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1
date: 2021-11-11
journal: Front Immunol
DOI: 10.3389/fimmu.2021.733921
sha: 06b3e8203e78b55baaba11c89cc18e7a48fb789d
doc_id: 894790
cord_uid: mbwbhdqe

A hallmark of COVID-19 is a hyperinflammatory state associated with severity. Monocytes undergo metabolic reprogramming and produce inflammatory cytokines when stimulated with SARS-CoV-2. We hypothesized that binding by the viral spike protein mediates this effect, and that drugs which regulate immunometabolism could inhibit the inflammatory response. Monocytes stimulated with recombinant SARS-CoV-2 spike protein subunit 1 showed a dose-dependent increase in glycolytic metabolism associated with production of pro-inflammatory cytokines. This response was dependent on hypoxia-inducible factor-1α, as chetomin inhibited glycolysis and cytokine production. Inhibition of glycolytic metabolism by 2-deoxyglucose (2-DG) or glucose deprivation also inhibited the glycolytic response, and 2-DG strongly suppressed cytokine production. Glucose-deprived monocytes rescued cytokine production by upregulating oxidative phosphorylation, an effect which was not present in 2-DG-treated monocytes due to the known effect of 2-DG on suppressing mitochondrial metabolism. Finally, pre-treatment of monocytes with metformin strongly suppressed spike protein-mediated cytokine production and metabolic reprogramming. Likewise, metformin pre-treatment blocked cytokine induction by SARS-CoV-2 strain WA1/2020 in direct infection experiments. In summary, the SARS-CoV-2 spike protein induces a pro-inflammatory immunometabolic response in monocytes that can be suppressed by metformin, and metformin likewise suppresses inflammatory responses to live SARS-CoV-2. This has potential implications for the treatment of hyperinflammation during COVID-19.

The ongoing coronavirus disease 2019 (COVID-19) pandemic has presently claimed more than 3 million lives worldwide as of mid-April 2021 (1) . COVID-19 is caused by a novel highly pathogenic coronavirus classified as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (2) . A hallmark of severe COVID-19 is hyperinflammation (3) , although cytokine expression patterns in individuals are diverse, leading to controversy over classification of COVID-19 related inflammation as cytokine storm, macrophage activation syndrome, multisystem inflammatory syndrome, etc. Regardless, inflammatory cytokines appear to play a principal role in mediating COVID-19 symptoms, therefore therapies which target these responses are paramount to treating severe COVID-19. As such, a fuller understanding of the cellular and molecular mechanisms mediating hypercytokinemia during SARS-CoV-2 infection is necessary.

Mononuclear phagocytes such as monocytes and macrophages are key constituents of the innate immune system, and produce proinflammatory cytokines during viral infection (4) (5) (6) (7) . We have previously suggested a key role for these cells in mediating severity of COVID-19 (7) (8) (9) . Monocyte and monocyte-derived macrophage infiltration into the lungs has been linked to severe COVID-19 in single cell RNA sequencing studies (10) (11) (12) (13) and postmortem analyses (14) (15) (16) (17) in human patients, as well as during experimental infections in animal models including mice (18, 19) , hamsters (20) , and various non-human primates (21) (22) (23) (24) (25) . Monocytes in individuals infected with SARS-CoV-2 display phenotypic changes associated with hyperinflammation, including reduced HLA-DR expression (26) (27) (28) , increased CD16 expression (27, (29) (30) (31) , and increased cytokine production (32) (33) (34) (35) . Both monocytes (36) (37) (38) and monocyte-derived macrophages (39, 40) also produce pro-inflammatory cytokines under direct infection with SARS-CoV-2, although infection at least in macrophages appears to be abortive (39, 40) .

The past decade has seen an explosion in scientific interest in the regulation of immune cell activation and function by metabolic reprogramming. Under pro-inflammatory conditions, immune cellsincluding myeloid cellsgenerally undergo a switch to aerobic glycolysis which provides ATP sufficient to support cellular functions which propagate pro-inflammatory and antipathogen host responses (41) . Recently, Codo et al. demonstrated pro-inflammatory glycolytic reprogramming in monocytes infected with SARS-CoV-2 (36) , and SARS-CoV-2 also appears to alter monocyte lipid metabolism to promote lipid droplet formation which is associated with pro-inflammatory cytokine production (37) .

SARS-CoV-2 therefore appears to reprogram metabolism in monocytes, but the viral factors which mediate these responses are unclear. Research in the 2003 epidemic SARS-CoV-1 suggested that the viral spike protein could mediate pro-inflammatory activation in macrophages (42, 43) , and recent evidence suggests the spike protein of SARS-CoV-2 also activates inflammatory responses in macrophages and monocytes both in vitro and in vivo (44, 45) . Given this, we hypothesized that spike protein binding to monocytes mediates glycolytic reprogramming to promote proinflammatory responses of these cells to SARS-CoV-2. Our results herein support this hypothesis, and we additionally report outcomes from experiments aimed at evaluating the responsible cellular signaling mechanisms, as well as potential pharmaceutical strategies for inhibiting these responses.

Healthy 18-35-year-old subjects (N=14) were recruited without respect to sex or race. Participants reported to the laboratory approximately every two weeks for blood collection, and 8-24 ml blood was collected into EDTA-treated vacutainer tubes by venipuncture. Blood was immediately used for cell isolations as described below.

Assays were performed on purified human classical monocytes isolated using immunomagnetic negative sorting (EasySep Direct Human Monocyte Isolation Kit, StemCell Technologies, Cambridge, MA). As we have previously described (46) , this procedure results in a highly pure (> 85%) population of classical monocytes, with depletion of intermediate and non-classical monocytes due to the presence of an anti-CD16 antibody in the cocktail. Isolation purity was verified at several points throughout the current study and averaged approximately 90% (not shown). Cells were counted at 10× dilution using a Scepter cell counter (Millipore Sigma, St. Louis, MO). Isolated monocytes were immediately utilized in downstream assays, and no cells were frozen for later use.

Unless otherwise specified, all assays were performed using Seahorse XF base DMEM medium (Agilent, Santa Clara, CA) supplemented with 10 mM glucose and 2 mM L-glutamine (Millipore Sigma, St. Louis, MO). Assays utilizing glucose deprivation omitted glucose from the media preparation. Media was not supplemented with fetal bovine serum or other additives. Recombinant spike protein subunit 1 (S1) was purchased from RayBiotech (Peachtree Corners, GA). 2deoxyglucose, chetomin, compound C, and metformin were purchased from Millipore Sigma (St. Louis, MO). SARS-CoV-2 WA1/2020 strain was provided by Dr. Colleen Jonsson, Regional Biocontainment Laboratory, University of Tennessee Health Science Center.

Glycolysis and oxidative phosphorylation were respectively quantified via kinetic monitoring of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) on a Seahorse XFp analyzer (Agilent, Santa Clara, CA). For all assays, monocytes were plated at 1.5×10 5 cells per well, and wells A and H of the XFp plate were background wells with no cells. All analyses were run in duplicate. Plated cells were incubated at 37°C in a non-CO 2 incubator for 1 hour prior to assays to stabilize pH. All wells were imaged at 10× magnification for cell counting in order to adjust raw measurements for cell number.

For quantification of dose response to S1, 5 basal measurements were made, followed by injection of media (wells B-C), 100 nM spike protein (wells D-E), or 300 nM spike protein (wells F-G). After injection into existing media in the well, spike protein concentrations were 10-fold lower than injection concentrations, thereby giving final spike protein concentrations of 0 nM, 10 nM, or 30 nM. Following injection, ECAR and OCR were monitored serially for 60 measurements. Following the assay, cell culture supernatants were removed, pooled by duplicate, and stored at -80°C. Cells were then lysed with 100 ml Trizol (Thermo Fisher Scientific, Waltham, MA), pooled by duplicate, and stored at -80°C as we have previously described (47) .

For chetomin and metformin Seahorse assays, cells were incubated in media as above (wells B-E), or either 10 nM chetomin or 50 mM metformin during the 1-hour preincubation period (wells F-G). 5 basal ECAR/OCR measurements were performed, followed by injection of media (wells B-C) or 300 nM spike protein (wells D-G) for a final concentration of 0 nM (wells B-C) or 30 nM spike protein (wells D-G) as above. Following injection, ECAR and OCR were monitored serially for 30 measurements. Cell culture supernatants and Trizol lysates were processed as described above following the end of the assay.

For glycolysis inhibition assays, cells were incubated in media, 10 mM 2-deoxyglucose, or media without glucose (glucose deprivation) during the 1-hour pre-incubation period. 5 basal ECAR/OCR measurements were performed, followed by injection of 300 nM spike protein to all wells for a final concentration of 30 nM spike protein per well as above. Spike protein was prepared in non-glucose media for the glucose deprivation condition. Following injection, ECAR and OCR were monitored serially for 30 measurements. Cell culture supernatants and Trizol lysates were processed as described above following the end of the assay.

Isolated monocytes were incubated in RPMI-1640 media (Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (Gibco), with or without 50 mM metformin, for 1-hour. Cells were then treated with media or infected with SARS-CoV-2 virus (WA1/2020 isolate) at 0.5 MOI and incubated for 24 hours. Cell culture supernatants were collected from untreated and infected cells and stored at -80°C until analysis. SARS-CoV-2 experiments were conducted under biosafety level 3 at the Regional Biocontainment Laboratory at the University of Tennessee Health Science Center.

RNA isolation was performed using the Trizol procedure based on manufacturer's instructions from cells lysed directly in the microplate or Seahorse plate wells as applicable. Isolated RNA (300-400 ng depending on experiment) was reverse-transcribed to cDNA using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA). Gene expression was analyzed using commercial pre-validated gene expression assays and Taqman reagents (Thermo Fisher Scientific, Waltham, MA). Relative gene expression was quantified using the 2 -DDCt method (48) against B2M or ACTB as housekeeping genes. Primer/probe IDs were: B2M Hs00187842_m1; ACTB Hs03023943_g1; IL1B Hs01555410_m1; IL6 Hs00174131_m1; CXCL8 Hs00174103_m1; TNF Hs00174128_m1; CPT1A Hs00912671_m1; G6PD Hs00166169_m1; HLA-DRA Hs0021957 5_m1; CDKN2A Hs00923894_m1; TLR4 H s 0 0 1 5 2 9 3 9 _ m 1 ; I L 1 0 H s 0 0 9 6 1 6 2 2 _ m 1 ; TGFB1 Hs00998133_m1.

For protein quantification, cell culture supernatants harvested from microplates or Seahorse XFp plates were analyzed via ELISA. Commercial DuoSet matched-antibody reagent sets were purchased from R&D Systems (Minneapolis, MN) for quantifying human IL-6, human IL-1b, human IL-8, and human TNFa and were used according to manufacturer's instructions. All samples were run in duplicate at 5× dilution (SARS-CoV-2 assays), or 50× dilution (Seahorse S1 dose response assays), or 10× dilution (all others) and assessed against a standard curve.

Protein concentration of angiotensin converting enzyme 2 (ACE2) and C-reactive protein (CRP) was performed by ELISA on plasma samples collected by venipuncture from subjects at the beginning of the study. Peripheral blood was collected by venipuncture into EDTA-coated vacutainer tubes, centrifuged at 1,500×g for 15 min, aliquoted, and stored at -80°C until analysis. Plasma samples were analyzed in duplicate at 10× (ACE2) or 10,000× (CRP) using commercial DuoSet matchedantibody reagent kits (R&D Systems) according to manufacturer's instructions and assessed against a standard curve. ACE2 and CRP data are included in the FigShare repository (49) , along with other clinical and anthropomorphic data for experimental subjects.

All data processing and statistical analyses were performed using R v. 3.6.2 (50) . Isolated monocytes from each subject were given all treatments for each experiment, so data were paired and analyzed using within-subjects designs. Data were checked for normality by Shapiro-Wilk test and analyzed by one-way repeated measures ANOVA (RM-ANOVA, for data which met the normality assumption) or Friedman's test (for data which did not meet the normality assumption). For analyses with significant main effects, post hoc mean separation was performed using pairwise paired T tests (for RM-ANOVA) or pairwise Wilcoxon signed-rank tests (for Friedman's tests) with p-value adjustment using the Holm-Bonferroni method (51) . Significance cutoff was p<0.05.

All raw data and analytical scripts (as R markdown files) are available in a dedicated FigShare repository (49) . This manuscript was posted to the preprint server bioRxiv prior to submission for publication (52) .

All human subjects activities were approved by the Institutional Review Board at the University of Memphis under protocol 4316, and subjects provided written informed consent prior to enrollment.

Recently it was demonstrated that SARS-CoV-2 promotes metabolic reprogramming in monocytes during infection (36, 37) . Research in SARS-CoV-1 suggested that the viral spike protein induces inflammatory responses in macrophages (42, 43) , and this has recently been replicated using spike protein from SARS-CoV-2 (44, 45) . Likewise, spike protein binding to C-type lectins has recently been shown to mediate proinflammatory processes in myeloid cells (53, 54) . Therefore, we hypothesized that the SARS-CoV-2 spike protein mediates a pro-inflammatory metabolic reprogramming in monocytes which could be a basis for hypercytokinemia. Stimulation of isolated human classical monocytes with recombinant spike protein subunit 1 (S1) from SARS-CoV-2 induced glycolytic a c t iv a t io n (F i g ur e 1 A ) a n d s u p p r e s s e d o x i d a t i v e phosphorylation (OXPHOS, Figure 1C ) in a dose-dependent manner. The effect of S1 dose was significant for both extracellular acidification rate (F 2,14 = 72.44, p<0.0001, Figure 1B ) and oxygen consumption rate (F 2,14 = 5.785, p=0.0147, Figure 1D ) as measured by quantification of area under the response curve.

Additionally, recombinant S1 treatment caused a dosedependent increase transcription of pro-inflammatory cytokines ( Figure 1E ) including IL1B (F 2,14 = 50.98, p<0.001), IL6 (Friedman c 2 (df=2) =16, p<0.001), CXCL8 (F 2,14 = 38.19, p<0.001), and TNF (F 2,14 = 28.41, p<0.001) as measured by qPCR. These cytokines have been implicated in the pathogenesis of SARS-CoV-2 and in COVID-19-related hypercytokinemia in several studies (27, (55) (56) (57) (58) (59) (60) . To confirm that increased transcription resulted in increased protein expression, we evaluated protein concentrations of key cytokines in the supernatant of S1-stimulated monocytes by enzyme-linked immunosorbent assay (ELISA) ( Figure 1F ). S1 increased protein expression of interleukin (IL)-6 (Friedman c 2 (df=2) =16, p<0.001) and tumor necrosis factor (TNF)-a (F 2,14 = 37.73, p<0.001) in a dose-dependent manner.

Recombinant S1 treatment also increased gene expression of the anti-inflammatory cytokine IL-10 (Wilcoxon Z=0, p=0.016, Figure 2A ) and decreased gene expression of the antiinflammatory cytokine TGF-b (Wilcoxon Z=28, p=0.016, Figure 2B ). We additionally analyzed gene expression for a variety of polarization and reprogramming markers ( Figure 2C) , and found that rS1 treatment increased expression of the senescence-associated gene for p16 (CDKN2A, t (df=5) =-2.985, p=0.031) as well as HLA-DRA (t (df=5) =-2.887, p=0.034). Treatment with 30 nM rS1 also reduced expression of metabolism-related genes G6PD (Wilcoxon Z=21, p=0.031) and CPT1A (t (df=5) =15.373, p<0.001) and the LPS receptor TLR4 (t (df=5) =4.833, p=0.005). Therefore, monocytes appear to be activated by S1 and upregulate expression of both pro-and anti-inflammatory cytokines, and additionally show gene expression patterns reflecting altered metabolism.

Hypoxia inducible factor (HIF)-1a was demonstrated nearly 20 years ago to mediate pro-inflammatory responses in myeloid cells (61) , and has more recently been shown to regulate glycolytic activation in monocytes, macrophages, and other immune cells (62) (63) (64) . SARS-CoV-2 activates HIF-1amediated glycolysis in monocytes (36) , so we reasoned that this was a likely downstream mechanism by which the viral spike protein causes this similar glycolytic reprogramming in our experiments. As above, treatment of monocytes with S1 activated glycolysis, and this effect was abrogated by pre-treatment with chetomin ( Figures 3A, B , F 2,12 = 42.43, p<0.001), which disrupts the interaction between HIF-1a and p300 to block the effects of the former (65) . Pre-treatment with chetomin also strongly suppressed the cytokine response due to S1 treatment ( Figure 3C) , including blunting transcription of IL1B (F 2,12 = 27.35, p<0.001), IL6 (F 2,12 = 16.11, p<0.001), CXCL8 (F 2,12 = 25.54, p<0.001), and TNF (F 2,12 = 29.04, p<0.001). Protein concentrations of these cytokines in culture supernatants showed similar patterns ( Figure 3D ). As such, HIF-1a appears to be a master regulator of both glycolytic reprogramming and inflammatory activation of monocytes under S1 stimulation.

To determine whether metabolic reprogramming is responsible for altered cytokine responses to S1, we suppressed glycolytic responses during S1 treatment using 2-deoxyglucose (2-DG) pretreatment. Treatment of monocytes with 2-DG ablated monocyte glycolytic responses to S1 stimulation ( Figure 4A ) which was significant by comparison of area under the response curve (t 6 =-10.867, p<0.0001, Figure 4B ). However, 2-DG also suppressed mitochondrial function in these cells ( Figure 4C) , though this was nonsignificant by area under the oxygen consumption (t 6 =-2.2284, p=0.0674, Figure 4D ). This effect has been noted previously during responses to LPS (66) . Anticipating this, we also included a condition where monocytes were cultured under glucose deprivation, as a second method of suppressing glycolytic activation. We noted a similar ablation of glycolytic responses to S1 using this strategy ( Figure 4A ) which was significant by area under the curve analysis (t 6 =-14.045, p<0.0001, Figure 4B ). However, glucose deprivation caused an increase in oxygen consumption after S1 treatment ( Figure 4C ) which was significant compared to media-(t 6 = 4.6618, p=0.0069) or 2-DG (t 6 =-15.607, p<0.001) pretreated monocytes ( Figure 4D) .

Pre-treatment of monocytes with 2-DG also strongly inhibited cytokine expression compared to cells treated with S1 ( Figure 4E) , including transcription of IL1B (W=0, p=0.0313), IL6 (t 6 =-5.912, p=0.0021), CXCL8 (W=0, p=0.0313), and TNF (W=0, p=0.0313). However, glucose deprived monocytes generally maintained their ability to transcribe pro-inflammatory cytokines in response to S1, with only IL1B expression showing a modest 25.1% reduction in glucose deprived compared to S1-treated monocytes ( Figure 4E , W=0, p=0.0313). Protein concentrations in cell culture supernatants followed gene expression patterns ( Figure 4F ).

Monocytes appear to utilize fatty acid oxidation to compensate for loss of glycolysis during cytokine responses as has been previously demonstrated with LPS (66-69), and therefore the 2-DGmediated suppression of S1-induced inflammation is likely due to its ability to suppress both glycolysis and mitochondrial metabolism in concert.

The small molecule compounds chetomin and 2-deoxyglucose inhibited immunometabolic activation in monocytes, suggesting a potential strategy for treating hypercytokinemia during COVID-19. However, chetomin is not approved for use in humans, although it has shown efficacy in vivo in animal models (65) . Additionally, 2-DG has poor efficacy in humans due to rapid metabolism and limited bioavailability (70) . Therefore, we investigated the ability of the common diabetes and geroprotector drug metformin to inhibit cytokine production in S1-stimulated monocytes. Metformin activates AMPK (71) and (independently of AMPK) opposes the action of HIF-1a (72, 73) , and additionally inhibits mitochondrial metabolism through blocking complex I of the electron transport chain (74, 75) , thus we hypothesized that it would have a qualitatively similar effect to 2-DG in inhibiting cytokine production through dual inhibition of glycolysis and OXPHOS. Pre-treatment with metformin abrogated the glycolytic response to S1 in monocytes ( Figures 5A, B, F 2 

Recent evidence suggests that myeloid cells recognize SARS-CoV-2 spike protein through C-type lectins (53, 54) . However, the SARS-CoV-2 virion also contains additional immunoregulatory and pro-inflammatory proteins (76, 77) , therefore we examined the ability of metformin to block cytokine responses to live SARS-CoV-2. Monocytes treated for 24 hr with SARS-CoV-2 increased expression of IL-6 protein, and this was suppressed by metformin pre-treatment ( Figure 5G , F 2,14 = 11.48, p=0.0011), suggesting that the anti-inflammatory effect of metformin is generalizable to SARS-CoV-2 infection of monocytes.

The present study resulted in several advances of major importance for the understanding of SARS-CoV-2 innate immune responses. First, we report here that monocytes treated with recombinant spike protein subunit 1 from the current pandemic SARS-CoV-2 undergo a dose-dependent increase in glycolysis which can be suppressed by a HIF-1a inhibitor and mediates the production of pro-inflammatory cytokines. These data suggest an initial signaling event which precipitates changes in glucose and lipid metabolism during SARS-CoV-2 infection in monocytes which have been previously reported to be linked to inflammatory activation (36, 37) . Monocyte and monocyte-derived macrophages are substantially enriched in the lungs of SARS-CoV-2-infected individuals with severe COVID-19 (10, 11, (14) (15) (16) (17) and respond to experimental viral infection by producing proinflammatory cytokines (36) (37) (38) (39) (40) , therefore these results reflect a potential mechanism by which hypercytokinemia occurs during the early innate immune response to SARS-CoV-2.

Importantly, the available evidence suggests that infection of monocytes/macrophages by SARS-CoV-2 is abortive (39, 40, 78) , thus recognition of SARS-CoV-2 structural proteins or genomic material is the likely mechanism by which direct infection precipitates inflammatory responses in this cell type. Our data suggest the spike protein is one such determinant, although we cannot conclude it is the only such mechanism given that recent reports have demonstrated inflammatory responses in macrophages treated with the SARS-CoV-2 envelope protein (76) . It is also possible, however, that direct viral binding to monocytes is not the only way in which these cells can be exposed to the viral spike protein. Recent evidence suggests that vaccine antigens including S1 are released into the circulation following vaccination (albeit at very low levels) (79) , and this represents a potential pro-inflammatory stimulus for monocytes. Monocyte/macrophage recognition of S1 may also contribute to the local (muscle) inflammatory response during vaccination. Additionally, the viral spike protein undergoes cleavage by furin during binding to ACE2 (80) , and it has been suggested that this could lead to release of the S1 subunit during infection (81) , although to date this is speculative. ACE2 has limited expression on immune cells including monocytes and macrophages (82) , which has called into question whether they can directly recognize SARS-CoV-2. In this study we did not identify the mechanism for monocyte recognition of S1, but several recent papers have shed light on this. Two reports recently demonstrated spike binding to C-type lectin receptors (53, 54) which mediates pro-inflammatory signaling in myeloid cells. Likewise, monocytes and macrophages express high levels of CD147 (82) , and this receptor has been shown to recognize spike protein and contribute to activation of T cells (83) . Monocytes therefore have multiple methods of recognizing S1, and the receptor(s) responsible for signaling to induce immunometabolic activation deserve further investigation.

The second major advance in this study is the identification of metformin as a potential immunometabolic regulator of inflammatory responses to SARS-CoV-2. Small molecule inhibitors of HIF-1a (chetomin) and glucose metabolism (2deoxyglucose) blocked cytokine production in S1-treated monocytes, suggesting that interfering with downstream signaling pathways activated by spike protein binding is a potential therapeutic strategy to target inflammation during COVID-19. As these compounds are not approved for human use or have low efficacy in humans as described above, we evaluated the ability of metformin to suppress glycolytic reprogramming and cytokine production in S1-stimulated monocytes. Metformin reduced cytokine production and strongly inhibited both glycolysis and cellular respiration in culture, suggesting it as a potential treatment for hyperinflammation during COVID-19. Further, metformin blocked IL-6 production in monocytes infected with live SARS-CoV-2, suggesting this effect is not limited to artificial stimulation conditions with purified recombinant protein.

However, we were unable to perform additional experiments using live SARS-CoV-2 to replicate further findings from this study, so a great deal of additional work is necessary to link our S1 data to our very preliminary SARS-CoV-2 observation. Metformin is extremely inexpensive compared to many pharmaceuticals, with an estimated manufacturing cost under 10 USD per kg for the active ingredient (84) and a monthly wholesale cost as low as 25 USD (85) . Metformin has been previously noted as a treatment for non-COVID acute respiratory distress syndrome (86) and is a potent suppressor of immune activation of monocytes and macrophages by other molecules including LPS (87) (88) (89) . Additionally, several epidemiological studies have noted decreased mortality (90) (91) (92) (93) (94) and inflammation (systemic C-reactive protein) (95, 96) in COVID-19 patients who were taking metformin prior to diagnosis. These effects varied between studies, with mortality reductions of 20% -80% across reports, but a meta-analysis found an overall reduction of 46% in mortality across 5 qualifying studies (94) . Therefore, given these observations and its low cost, excellent safety profile, wide availability, and efficacy in inhibiting inflammatory responses to S1 in vitro, metformin is a promising candidate for further exploration as a COVID-19 therapeutic. Our study is limited to a single in vitro measure of metformin as a therapeutic for COVID-19, so a great deal of further study is necessary in order to establish this drug as a viable treatment. To this end, one recent study demonstrated metformin as efficacious in preventing acute respiratory distress syndrome in a preclinical animal model of COVID-19 (97) . Therefore, although metformin is most likely to be useful as an adjuvant rather than front-line therapy for severe acute COVID-19, it remains an attractive option for targeting hyperinflammation in this disease to limit severity and mortality.

Limitations of this study include the small sample size, although the large effect sizes in most experiments are sufficient to convincingly demonstrate the interrogated mechanisms. More significantly, this study relies on healthy younger subjects and so does not address how comorbidities such as aging or obesity would affect the measured outcomes or the efficacy of the therapies we tested. We determined this to be appropriate, given our focus on mechanistic investigation in this study. However, further research is needed to determine if other populations have different responses to S1 and/or metformin. We additionally did not recruit with respect to race or sex and therefore have a relatively diverse sample which could increase variability. However, the magnitude of the responses did not show patterns consistent with race-or sex-based differences in our outcome measures. While it is conceivable that such differences exist, the effects are likely to be small enough that large studies would be necessary to detect small betweenpopulation differences. Finally, none of our subjects were previously taking metformin, and the ability of in vivo metformin to modulate monocyte responses to S1 requires further study.

In summary, we demonstrate here that the spike protein subunit 1 from SARS-CoV-2 causes activation of HIF-1a dependent glycolysis and inflammatory cytokine production in monocytes which can be suppressed by treatment with the diabetes drug metformin. These experiments detail a mechanism by which SARS-CoV-2 mediates metabolic reprogramming previously described in human monocytes, and additionally provides a potential mechanism for the observation that metformin is protective against mortality in COVID-19 patients. Continued research in this area has the potential to define therapeutic strategies and additional molecular targets for the treatment of COVID-19-associated hyperinflammation.

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://figshare.com/, DOI: 10.6084/m9.figshare.c.5463525.

The studies involving human participants were reviewed and approved by the University of Memphis Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

BP conceived the study. TC and BP designed experiments. TC, RE, JY, KD, and BP collected data. BP analyzed data and prepared the first manuscript draft. TC, RE, JY, KD, and BP edited the manuscript draft. All authors read and approved the final manuscript.

The study was primarily supported by a University of Memphis/ University of Tennessee Health Science Center Collaborative Research Network (CORNET) award to BP and TC, with additional support from American Heart Association grants 18AIREA33961089 and 19TPA34910232 to BP, and a University of Memphis College of Health Sciences faculty research grant to BP. RE was supported by a postdoctoral fellowship funded by the University of Memphis Division of Research and Innovation through the Carnegie R1 Postdoc Program.

The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming it SARS-CoV-2

Clinical and Immunological Features of Severe and Moderate Coronavirus Disease

Respiratory Mononuclear Phagocytes in Human Influenza A Virus Infection: Their Role in Immune Protection and As Targets of the Virus

Respiratory Syncytial Virus and Asthma: The Role of Monocytes

Monocytes and Macrophages as Viral Targets and Reservoirs

Severe COVID-19 and Aging: Are Monocytes the Key? GeroScience (2020)

Aging and Monocyte Immunometabolism in COVID-19

Atypical Monocytes in COVID-19: Lighting the Fire of Cytokine Storm?

Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19

The Differential Immune Responses to COVID-19 in Peripheral and Lung Revealed by Single-Cell RNA Sequencing

Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19

COVID-19 Immune Features Revealed by a Large-Scale Single-Cell Transcriptome Atlas

Immunological and Inflammatory Profiles in Mild and Severe Cases of COVID-19

Two Distinct Immunopathological Profiles in Autopsy Lungs of COVID-19

Pathological Findings of Postmortem Biopsies From Lung, Heart, and Liver of 7 Deceased COVID-19 Patients

Clinical and Pathological Investigation of Patients With Severe COVID-19

SARS-CoV-2 Infection of Human ACE2-Transgenic Mice Causes Severe Lung Inflammation and Impaired Function

The Pathogenicity of SARS-CoV-2 in Hace2 Transgenic Mice

Pathogenesis and Transmission of SARS-CoV-2 in Golden Hamsters

Delayed Severe Cytokine Storm and Immune Cell Infiltration in SARS-CoV-2-Infected Aged Chinese Rhesus Macaques

Infection With Novel Coronavirus (SARS-CoV-2) Causes Pneumonia in Rhesus Macaques

SARS-CoV-2 Infection Protects Against Rechallenge in Rhesus Macaques

Single-Cell RNA Sequencing Reveals SARS-CoV-2 Infection Dynamics in Lungs of African Green Monkeys

Cellular Events of Acute, Resolving or Progressive COVID-19 in SARS-CoV-2 Infected Non-Human Primates

Complex Immune Dysregulation in COVID-19 Patients With Severe Respiratory Failure

A Dynamic COVID-19 Immune Signature Includes Associations With Poor Prognosis

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

A Longitudinal Study of Immune Cells in Severe COVID-19 Patients

Longitudinal Immune Profiling Reveals Key Myeloid Signatures Associated With COVID-19

Major Alterations in the Mononuclear Phagocyte Landscape Associated With COVID-19 Severity

Unique Immunological Profile in Patients With COVID-19

Multi-Omics Resolves a Sharp Disease-State Shift Between Mild and Moderate COVID-19

Single-Cell Analysis of Two Severe COVID-19 Patients Reveals a Monocyte-Associated and Tocilizumab-Responding Cytokine Storm

Mismatch Between Circulating Cytokines and Spontaneous Cytokine Production by Leukocytes in Hyperinflammatory COVID-19

Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response Through a HIF-1a/Glycolysis-Dependent Axis

Replication and Production of Inflammatory Mediators

SARS-CoV-2 Engages Inflammasome and Pyroptosis in Human Primary Monocytes

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells

Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells is Associated With Viral Antagonism of STAT1 Phosphorylation

A Guide to Immunometabolism for Immunologists

Up-Regulation of IL-6 and TNF-a Induced by SARS-Coronavirus Spike Protein in Murine Macrophages via NF-kB Pathway

SARS Coronavirus Spike Protein-Induced Innate Immune Response Occurs via Activation of the NF-kB Pathway in Human Monocyte Macrophages In Vitro

Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein

Nucleocapsid and Spike Proteins of the Coronavirus Sars-Cov-2 Induce Il6 in Monocytes and Macrophages-Potential Implications for Cytokine Storm Syndrome

Aging Impairs Mitochondrial Respiratory Capacity in Classical Monocytes

Classical Monocytes Maintain Ex Vivo Glycolytic Metabolism and Early But Not Later Inflammatory Responses in Older Adults

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-DDCT Method

Data for Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 and Spike Protein Subunit 1

R: A Language and Environment for Statistical Computing

A Simple Sequentially Rejective Multiple Test Procedure

Metformin Suppresses Immunometabolic Activation by SARS-CoV-2 and Spike Protein Subunit 1. bioRxiv

DC/L-SIGN Recognition of Spike Glycoprotein Promotes SARS-CoV-2 Trans-Infection and can be Inhibited by a Glycomimetic Antagonist

SARS-CoV-2 Exacerbates Proinflammatory Responses in Myeloid Cells Through C-Type Lectin Receptors and Tweety Family Member

Inflammasomes are Activated in Response to SARS-Cov-2 Infection and are Associated With COVID-19 Severity in Patients

Early IL-1 Receptor Blockade in Severe Inflammatory Respiratory Failure Complicating COVID-19

Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

An Inflammatory Cytokine Signature Predicts COVID-19 Severity and Survival

Scoring Cytokine Storm by the Levels of MCP-3 and IL-8 Accurately Distinguished

Patients With High Mortality

HIF-1a Is Essential for Myeloid Cell-Mediated Inflammation

Succinate Is an Inflammatory Signal That Induces IL-1 Beta Through HIF-1 Alpha

NF-kB Links Innate Immunity to the Hypoxic Response Through Transcriptional Regulation of HIF-1a

HIF1a and Metabolic Reprogramming in Inflammation

Small Molecule Blockade of Transcriptional Coactivation of the Hypoxia-Inducible Factor Pathway

Fatty Acid Oxidation Compensates for Lipopolysaccharide-Induced Warburg Effect in Glucose-Deprived Monocytes

Classical Monocytes From Older Adults Maintain Capacity for Metabolic Compensation During Glucose Deprivation and Lipopolysaccharide Stimulation

Adherence Affects Monocyte Innate Immune Function and Metabolic Reprogramming After Lipopolysaccharide Stimulation In Vitro

Tissue-Resident Alveolar Macrophages do Not Rely on Glycolysis for LPS-Induced Inflammation

2-Deoxy-D-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents

Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action

Tubular Injury in a Rat Model of Type 2 Diabetes is Prevented by Metformin: A Possible Role of HIF-1a Expression and Oxygen Metabolism

Metformin Suppresses Hypoxia-Induced Stabilization of HIF-1' Through Reprogramming of Oxygen Metabolism in Hepatocellular Carcinoma

Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I

Evidence That Metformin Exerts its Anti-Diabetic Effects Through Inhibition of Complex 1 of the Mitochondrial Respiratory Chain

TLR2 Senses the SARS-CoV-2 Envelope Protein to Produce Inflammatory Cytokines

SARS-CoV-2 Membrane Glycoprotein M Antagonizes the MAVS-Mediated Innate Antiviral Response

Monocytes and Macrophages, Targets of SARS-CoV-2: The Clue for Covid-19

Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

Loss of Furin Cleavage Site Attenuates SARS-CoV-2 Pathogenesis

Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection

Distribution of ACE2, CD147, CD26, and Other SARS-CoV-2 Associated Molecules in Tissues and Immune Cells in Health and in Asthma, COPD, Obesity, Hypertension, and COVID-19 Risk Factors

CD147-Spike Protein is a Novel Route for SARS-CoV-2 Infection to Host Cells

Estimated Costs of Production and Potential Prices for the WHO Essential Medicines List

Medicines for Rheumatoid Arthritis: A Review of the Research for Adults

Metformin Relieves Acute Respiratory Distress Syndrome by Reducing miR-138 Expression

Metformin Suppresses Lipopolysaccharide (LPS)-Induced Inflammatory Response in Murine Macrophages via Activating Transcription Factor-3 (ATF-3) Induction

Metformin Inhibits the Production of Reactive Oxygen Species From NADH: Ubiquinone Oxidoreductase to Limit Induction of Interleukin-1b (IL-1b) and Boosts Interleukin-10 (IL-10) in Lipopolysaccharide (LPS)-Activated Macrophages

Metformin, an Antidiabetic Agent, Suppresses the Production of Tumor Necrosis Factor and Tissue Factor by Inhibiting Early Growth Response Factor-1 Expression in Human Monocytes In Vitro

Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes

Metformin and Risk of Mortality in Patients Hospitalised With COVID-19: A Retrospective Cohort Analysis

Phenotypic Characteristics and Prognosis of Inpatients With COVID-19 and Diabetes: The CORONADO Study

Metformin Treatment was Associated With Decreased Mortality in COVID-19 Patients With Diabetes in a Retrospective Analysis

Metformin Use is Associated With Reduced Mortality Rate From Coronavirus Disease 2019 (COVID-19) Infection

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

Metformin Is Associated With Higher Incidence of Acidosis, But Not Mortality, in Individuals With COVID-19 and Pre-Existing Type 2 Diabetes

Metformin Inhibition of Mitochondrial ATP and DNA Synthesis Abrogates NLRP3 Inflammasome Activation and Pulmonary Inflammation

The authors would like to acknowledge the participants in this study. The authors thank Jyothi Parvathareddy and Colleen Jonsson from the Regional Biocontainment Laboratory at the University of Tennessee Health Science Center for providing SARS-CoV-2 virus stocks.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2021 Cory, Emmons, Yarbro, Davis and Pence. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.